摘要
目的探讨吉西他滨在膀胱癌灌注化疗中的有效性和安全性。方法选取2013年3月至2015年3月在我科接受经尿道膀胱肿瘤电切术(TURBT)辅以膀胱灌注化疗的80例膀胱癌患者作为研究对象,随机分为A、B两组,每组40例。A组灌注1 000 mg吉西他滨,B组灌注30mg吡柔比星。所有患者随访2年,根据随访资料比较两组患者的2年生存率、复发率、肿瘤进展发生率及不良反应发生情况。结果膀胱肿瘤总复发率为46.25%,其中A组复发率为35.00%,B组复发率为57.50%,A组复发率显著低于B组,差异有统计学意义(P<0.05);复发为非肌层浸润性膀胱癌的A组约30.00%,B组为45.00%,两组间差异无统计学意义(P>0.05);复发进展为肌层浸润性膀胱癌的A组约5.00%,B组为12.50%,两组间差异无统计学意义(P>0.05)。两组患者不良反应发生率差异无统计学意义。结论 TURBT术后采用吉西他滨进行膀胱灌注,能较好地预防非肌层浸润性膀胱癌的复发或进展,且安全性较高,值得推广。
Objective To evaluate the efficacy and safety of intravesical gemcitabine therapy for non-muscle-invasive bladder cancer（NMIBC）. Methods From March 2013 to March 2015 in our hospital,80 cases with NMIBC were selected as the research objects,and they were divided into two groups,（40 cases in each group）according to the treatment.Patients of A group were treated by intravesical gemcitabine therapy after TURBT,while patients of B group by pirarubicin.All patients were followed up for two years,then we compared two-year survival rate,recurrence rate,incidence of tumor progression and adverse reactions between the two groups. Results Total bladder tumor recurrence rate was 46.25%,gemcitabine group＇s recurrence rate was 35.00%,and pirarubicin group was 57.50%.The recurrence rate of gemcitabine group was significantly lower than that of pirarubicin group.Recurrence of non-muscle-invasive was about 30.00% in group A and group B 45.00%,which showed no statistical difference between the two groups（P〈0.05）.For invasive bladder cancer recurrence progressed about 5.00% in group A,and 12.50% in group B,which showed no statistical difference between the two groups（P〈0.05）.Also,no statistical difference was found in incidence of adverse reactions between two groups. Conclusions Intravesical chemotherapy with gemcitabine after TURBT is well tolerated and effective in preventing recurrence and disease progression for patients with NMIBC,so it is worth promoting.
出处
《现代泌尿生殖肿瘤杂志》
2017年第5期265-268,共4页
Journal of Contemporary Urologic and Reproductive Oncology
关键词
吉西他滨
膀胱灌注
非肌层浸润性膀胱癌
Gemcitabine
Intravesical irrigation
Non muscle invasive bladder cancer
